Lamotrigine in the maintenance treatment of bipolar disorder
Since lamotrigine is weaker than lithium at preventing manic episodes, what is our plan if I start noticing early manic symptoms?
Top of the evidence hierarchy, independently funded. how we score evidence
Caveat on this rating: The reviewers note that 8 of the 11 included trials were funded by the same manufacturer, so industry sponsorship bias in the underlying trials cannot be ruled out.
Across 11 trials with 2,314 participants, lamotrigine lowered the chance of a mood recurrence compared with placebo (risk ratio 0.67 for manic recurrence) and caused fewer side effects than lithium, but manic episodes were about twice as likely on lamotrigine as on lithium.
Worth asking
Since lamotrigine is weaker than lithium at preventing manic episodes, what is our plan if I start noticing early manic symptoms?
What it is FDA approved for
Read off the label. Trial duration and approval year are shown only where they were recorded — never inferred.
- Maintenance treatment of bipolar I disorder (to delay time to occurrence of mood episodes, after acute stabilization)
- Epilepsy, adjunctive therapy (partial-onset seizures, primary generalized tonic-clonic seizures, Lennox-Gastaut syndrome; ages 2+)
- Epilepsy, conversion to monotherapy for partial-onset seizures (ages 16+)
Source
Lamotrigine in the maintenance treatment of bipolar disorder — Hashimoto Y, et al. (2021)
Top-tier peer-reviewed journal
Read the source: https://doi.org/10.1002/14651858.CD013575.pub2
DOI: 10.1002/14651858.CD013575.pub2
How this was scored
- Study design
- Meta-analysis of randomised trials
- Funding
- Independently funded
- Published in
- Top-tier peer-reviewed journal
- Sample size
- 2,314
- Preregistered
- Yes
- Conflicts disclosed
- Yes
- Independent of proponent
- Yes
- Retracted
- No
Read the full scoring rubric, including what it can't tell you.
Published August 19, 2026.
Questions
How strong is the evidence behind this?
Resolv rates this source "gold standard". Top of the evidence hierarchy, independently funded. It scores 98 out of 100 on our published rubric. One caveat travels with that badge: The reviewers note that 8 of the 11 included trials were funded by the same manufacturer, so industry sponsorship bias in the underlying trials cannot be ruled out. The score is calculated from recorded facts about the source — study design, funding, publication venue, sample size, preregistration — not typed in by an editor.
What is the source for this?
Lamotrigine in the maintenance treatment of bipolar disorder — Hashimoto Y, et al. (2021). Published in: Top-tier peer-reviewed journal. DOI: 10.1002/14651858.CD013575.pub2. The full source is linked on this page so you can read it yourself.
Who paid for this research, and does that matter?
Study design: Meta-analysis of randomised trials. Funding: Independently funded. The researchers were independent of whoever benefits from the result. Industry sponsorship is one of the most reliably measured biases in medicine, which is why funding carries real weight in the score rather than sitting in a footnote.
Is lamotrigine (Lamictal), lamictal FDA approved?
Yes — FDA approved for Maintenance treatment of bipolar I disorder (to delay time to occurrence of mood episodes, after acute stabilization), Epilepsy, adjunctive therapy (partial-onset seizures, primary generalized tonic-clonic seizures, Lennox-Gastaut syndrome; ages 2+), Epilepsy, conversion to monotherapy for partial-onset seizures (ages 16+). Approval is for a specific indication, not for everything the drug is prescribed for.
Is this medical advice?
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.